Vamsidhara Vemireddy

Vamsidhara Vemireddy

Auto-generated profile, based on publicly available information

Vamsidhara Vemireddy

Division of Nephrology, Department of Internal Medicine, and Department of Pharmacology, University of Texas Southwestern, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Cell
Verified
Journal Article
Closed access
TMTomoyuki Mashimo
Tomoyuki Mashimo
KPKumar Pichumani
Kumar Pichumani
VVVamsidhara Vemireddy
Vamsidhara Vemireddy
KHKimmo J. Hatanpaa
Kimmo J. Hatanpaa
DSDinesh Kumar Singh
Dinesh Kumar Singh
RBRobert M. Bachoo
Robert M. Bachoo

1 June 2012 in Cell Metabolism
Verified
Journal Article
Closed access
IMIsaac Marin-Valencia
Isaac Marin-Valencia
CYChendong Yang
Chendong Yang
TMTomoyuki Mashimo
Tomoyuki Mashimo
SCSteve Cho
Steve Cho
HBHyeonman Baek
Hyeonman Baek
RBRobert M. Bachoo
Robert M. Bachoo

10 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KSKoji Sagiyama
Koji Sagiyama
TMTomoyuki Mashimo
Tomoyuki Mashimo
OTOsamu Togao
Osamu Togao
VVVamsidhara Vemireddy
Vamsidhara Vemireddy
KHKimmo J. Hatanpaa
Kimmo J. Hatanpaa
MTMasaya Takahashi
Masaya Takahashi
Significance: The prognosis and management of patients with glioma is vastly different depending on whether one detects tumor progression or treatment effects. Although the gold standard in the evaluation of treatment efficacy involves MRI, the currently available imaging methods often do not suffice to make the final decision. Our study demonstrated that amide proton transfer (APT) imaging, one subset of chemical exchange saturation transfer imaging, can detect molecular signals in glioma induced by short-term chemotherapy with temozolomide. These molecular events precede morphologic changes. The APT signal did not decrease in tumors resistant to chemotherapy. APT imaging may provide a useful prognostic biomarker of treatment response or tumor progression in glioma.

1 March 2012 in NMR in Biomedicine
Verified
Journal Article
Closed access
PDF file
IMIsaac Marin‐Valencia
Isaac Marin‐Valencia
SCSteve K. Cho
Steve K. Cho
DRDinesh Rakheja
Dinesh Rakheja
KHKimmo J. Hatanpaa
Kimmo J. Hatanpaa
PKPayal Kapur
Payal Kapur
RBRobert M. Bachoo
Robert M. Bachoo

17 March 2014 in Oncogene
Verified
Journal Article
Open access
PDF file
CCCristel Camacho
Cristel Camacho
PTP K Todorova
P K Todorova
MHM C Hardebeck
M C Hardebeck
NTN Tomimatsu
N Tomimatsu
CAC R Gil del Alcazar
C R Gil del Alcazar
SBS Burma
S Burma
Glioblastomas (GBM) are highly radioresistant and lethal brain tumors. Ionizing radiation (IR)-induced DNA double-strand breaks (DSBs) are a risk factor for the development of GBM. In this study, we systematically examined the contribution of IR-induced DSBs to GBM development using transgenic mouse models harboring brain-targeted deletions of key tumor suppressors frequently lost in GBM, namely Ink4a, Ink4b, Arf and/or PTEN. Using low linear energy transfer (LET) X-rays to generate simple breaks or high LET HZE particles (Fe ions) to generate complex breaks, we found that DSBs induce high-grade gliomas in these mice which, otherwise, do not develop gliomas spontaneously. Loss of Ink4a and Arf was sufficient to trigger IR-induced glioma development but additional loss of Ink4b significantly increased tumor incidence. We analyzed IR-induced tumors for copy number alterations to identify oncogenic changes that were generated and selected for as a consequence of stochastic DSB events. We found Met amplification to be the most significant oncogenic event in these radiation-induced gliomas. Importantly, Met activation resulted in the expression of Sox2, a GBM cancer stem cell marker, and was obligatory for tumor formation. In sum, these results indicate that radiation-induced DSBs cooperate with loss of Ink4 and Arf tumor suppressors to generate high-grade gliomas that are commonly driven by Met amplification and activation.

12 February 2014 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
KHKimmo J. Hatanpaa
Kimmo J. Hatanpaa
THTianshen Hu
Tianshen Hu
VVVamsidhara Vemireddy
Vamsidhara Vemireddy
CFChan Foong
Chan Foong
JRJack M. Raisanen
Jack M. Raisanen
RBRobert M. Bachoo
Robert M. Bachoo